Core Viewpoint - GIC Private Limited has increased its stake in Basilea Pharmaceutica AG, reflecting strong confidence in the company's long-term value and growth potential [1] Group 1: GIC's Investment Activity - On November 10, GIC Private Limited acquired 1.7955 million shares of Basilea Pharmaceutica AG at a price of HKD 5.4692 per share, totaling approximately HKD 9.8199 million [1] - Following this purchase, GIC's total shareholding in Basilea has risen to approximately 105 million shares, representing a 7.11% ownership stake [1] - Since October 13, GIC has cumulatively increased its holdings by over 16 million shares, demonstrating a clear and sustained interest in the company [1] Group 2: Management Confidence - Basilea's CEO and key executives have also shown confidence in the company by purchasing shares multiple times since the second half of this year [1] - These insider purchases indicate a belief in the company's ability to maintain stable operations and achieve continuous growth [1] Group 3: Market Outlook - The dual support from international long-term capital and internal management enhances the outlook for Basilea's market performance and strategic positioning [1]
GIC连续加码基石药业-B(02616) 持股比例升至7.11%